Sanofi ADR
USUSDSanofi ADR (PA:SAN) — Biotechnology: Pharmaceutical Preparations. Broj burzi na kojima se trguje dionicama tvrtke: 6. Na ovoj stranici — cijena i grafikon, dividende, najveći dioničari i povijest broja dionica.
O tvrtki
- Web-stranica
- sanofi.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sjedište
- PARIS, France
- Glavni direktor
- Paul Hudson
- Zaposlenici
- 106 566
- Osnovana
- 2004
- Na burzi od
- 03.01.2000 (PA:SAN)
- Dionice u optjecaju
- 1.22 mlrd. na dan 2025-12-31
- Slobodno prenosive dionice
- 2.16 mlrd.
- Tržišna kapitalizacija
- 98.67 mlrd. USD
- Insajderi
- 0%
- Institucionalni ulagači
- 8.02%
- Djelatnost (SIC)
- Pharmaceutical Preparations
- Pravni oblik
- QVPB
- ISIN
- FR0000120578
- LEI
- 549300E9PC51EN656011
- Omjer isplate
- 0%
- FCF
- 10.8 mlrd. EUR
- Dug
- 18.7 mlrd. EUR1.0 g. FCF
- Dividendni staž
- 23 g.
- Zarada, FCF i isplaćene dividende — za 12 mjeseci do 31.12.2025 (najnovije izvješće tvrtke).
Opis
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Burze i oznake
| Burza | Oznaka | Valuta | Cijena | Vrsta |
|---|---|---|---|---|
| US USA Stocks | SNYNF OTC | USD | 78.99 -1.19% | obične dionice |
| LSE London Stock Exchange | 0O59 IOB | EUR | 71.63 +0.72% | obične dionice |
| MI Borsa Italiana (Milan) | 1SAN dodatna | EUR | 71.64 +0.90% | obične dionice |
| PA Euronext Paris | SAN glavna | EUR | 71.52 +0.83% | obične dionice |
| VI Vienna Stock Exchange | SANO dodatna | EUR | 71.3 +1.03% | obične dionice |
| XETRA Xetra | SNW dodatna | EUR | 71.78 -1.21% | obične dionice |
Dividende
Sanofi ADR (SAN) isplaćuje dividende jednom godišnje. U posljednjih 12 mjeseci isplaćeno je 4.12 EUR po dionici (isplate: 1). To je otprilike 5.76% trenutne cijene dionice. Prema povijesti isplata, sljedeći datum ex-dividende očekuje se oko 04.05.2027. Godine neprekinutih dividendi: 23.
| Ex-datum | Isplata | Iznos | % | Vrsta | Oznaka |
|---|---|---|---|---|---|
| 2026-05-05 | 2026-05-07 | 4.1200 EUR | 5.8/5.8 % | godišnji | PA:SAN |
| 2025-05-12 | 2025-05-14 | 3.9200 EUR | 5.5/5.5 % | godišnji | PA:SAN |
| 2024-05-13 | — | 3.7600 EUR | 5.3/10.2 % | godišnji | PA:SAN |
| 2023-05-30 | — | 3.5600 EUR | 5.0/5.0 % | godišnji | PA:SAN |
| 2022-05-06 | — | 3.3300 EUR | 4.7/4.7 % | godišnji | PA:SAN |
Vijesti ovog tjedna
Još nema vijesti s web-stranice tvrtke.
Najveći imatelji
| Imatelj | Udio | Dionice | Datum izvješća |
|---|---|---|---|
| Dodge & Cox Inc. | 10.54% | 28.09 mil. | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 7.84% | 20.9 mil. | 2026-06-30 |
| Morgan Stanley | 4.02% | 10.7 mil. | 2026-06-30 |
| Fisher Asset Management,… | 3.99% | 10.63 mil. | 2026-06-30 |
| Bank of America Corporat… | 3% | 8.01 mil. | 2026-06-30 |
| Invesco Ltd. | 2.55% | 6.8 mil. | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.47% | 6.57 mil. | 2026-06-30 |
| Mondrian Investment Part… | 2.07% | 5.52 mil. | 2026-06-30 |
| Brandes Investment Partn… | 1.55% | 4.14 mil. | 2026-06-30 |
| AIM Sector Funds (Invesc… | 1.51% | 4.03 mil. | 2026-04-30 |
| Federated Hermes, Inc. | 1.44% | 3.85 mil. | 2026-06-30 |
| Boston Partners | 1.44% | 3.84 mil. | 2026-06-30 |
| VANGUARD STAR FUNDS-Vang… | 1.31% | 15.85 mil. | 2026-07-31 |
| Putnam ETF Trust-Putnam… | 1.26% | 3.36 mil. | 2026-05-31 |
| VANGUARD TAX-MANAGED FUN… | 0.87% | 10.53 mil. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.67% | 8.11 mil. | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.63% | 1.67 mil. | 2026-06-30 |
| AMERICAN MUTUAL FUND | 0.59% | 1.58 mil. | 2026-06-30 |
| American Century Capital… | 0.37% | 976 561 | 2026-06-30 |
| Bridge Builder Trust-Bri… | 0.36% | 967 100 | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 4.24 mil. | 2026-07-31 |
| VanEck ETF Trust-VanEck… | 0.35% | 938 561 | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.33% | 4.04 mil. | 2026-06-30 |
| iShares Trust-iShares MS… | 0.32% | 3.89 mil. | 2026-08-31 |
| Capital World Growth & I… | 0.3% | 3.67 mil. | 2026-06-30 |
| -Victory Pioneer Core Eq… | 0.3% | 799 487 | 2026-06-30 |
| Fidelity Covington Trust… | 0.3% | 797 184 | 2026-08-31 |
| NEW PERSPECTIVE FUND | 0.29% | 3.56 mil. | 2026-06-30 |
| Federated Hermes Eqy. Fd… | 0.29% | 3.48 mil. | 2026-07-31 |
| Bridge Builder Trust-Bri… | 0.29% | 3.44 mil. | 2026-06-30 |
| Pacer Advisors, Inc. | 0.1% | 1.16 mil. | 2026-06-30 |
| Generali Investments Cee… | 0% | 29 339 | 2026-06-30 |
| Paradigm Asset Managemen… | 0% | 19 200 | 2026-06-30 |
| Gamma Investing LLC | 0% | 58 | 2026-06-30 |
| L'Oréal | — | — | — |
